09.14.26 -- Humacyte To Begin Testing Bioengineered Blood Vessel In Heart Bypass Surgery

How can life sciences companies developing new medicines engage the FDA successfully during a period of rapid changes in agency personnel and policies?  Register for 9-15-26 Crossing The Valley Of Death: New Funding Options For Preclinical And Early-Stage Drug Development for free and learn from an experienced panel of experts about key changes at the FDA, how companies can get the most out of agency interactions, and strategies to lower risks and avoid regulatory surprises. 

An upcoming first-in-human clinical trial will assess whether an off-the-shelf bioengineered blood vessel can provide a safe alternative to patient-harvested veins in coronary artery bypass surgery.

Stay at the forefront of digital innovation in healthcare and understand how artificial intelligence is revolutionizing Health Economics and Outcomes Research (HEOR) in this insightful video.

Many CNS trials today operate in a highly competitive environment. Enrollment success is shaped by the decisions teams make under these constraints.

Observe how integrated project management and co-located DS/DP operations streamline technology transfer, reduce risks, and accelerate biopharmaceutical development timelines.

Uncover how innovative reagent selection accelerates the development of promising drug-like molecules in challenging research environments.

See how this organization offers startups and entrepreneurs specialized facilities, unique incentives and programs that support their fundraising, and access to numerous research partners.